

RECEIVED  
CENTRAL FAX CENTER

DEC 06 2006

Appl. No. 10/602,441 (Docket 086/002)  
Amdt. dated December 6, 2006  
Reply to Office Action of June 6, 2006Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

What is claimed as the invention is:

1. *(Currently amended)* A method for eliciting an immune response in a ~~mammalian-subject~~ human ~~that is specific for its own~~ to human telomerase reverse transcriptase (TERT), comprising administering to the ~~subject~~ human an immunogenic composition containing a ~~protein with at least 20 consecutive amino acids of TERT of another non-human mammalian species, or a nucleic acid encoding said protein~~ a protein with at least 20 consecutive amino acids of TERT of a non-human mammalian species.
2. *(Currently amended)* The method of claim 1, wherein the protein comprises at least 100 consecutive amino acids of TERT of ~~the other mammalian species~~ a non-human mammalian species.
3. *(Currently amended)* The method of claim 1, comprising administering the ~~protein or~~ nucleic acid to the ~~subject~~ human on at least four different occasions.
4. *(Currently amended)* The method of claim 1, further comprising subsequently administering a second composition containing a second ~~protein with at least 20 consecutive amino acids of TERT of the same species as the subject, or a nucleic acid encoding said second protein~~ a protein with at least 20 consecutive amino acids of human TERT.
5. *(Original)* The method of claim 1, which elicits a cytotoxic T cell response.

Appl. No. 10/602,441 (Docket 086/002)

Amdt. dated December 6, 2006

Reply to Office Action of June 6, 2006

6. *(Currently amended)* The method of claim 1, wherein the protein is a full-length TERT.
- 7.-8. *(Canceled)*
9. *(Currently amended)* The method of claim 1, wherein the composition contains either:  
~~a plurality of different proteins, each comprising at least 20 consecutive amino acids of TERT from one or more mammalian species different from the mammalian subject to which the composition is administered, or~~  
one or more nucleic acids encoding ~~said plurality of proteins~~ a plurality of different proteins, each comprising at least 20 consecutive amino acids of TERT from one or more non-human mammalian species.
10. *(Currently amended)* The method of claim 1, wherein the protein comprises at least 20 consecutive amino acids of any of SEQ. ID NOs: 4, 6, 8, and 10, ~~and 12~~.
11. *(Original)* The method of claim 1, wherein the composition contains an adenovirus expression vector encoding the protein.
12. *(Original)* The method of claim 1, wherein the composition also contains a factor selected from IL-12, GM-CSF, IL-2 and MPL.
13. - 24. *(Canceled)*